Viz.ai and Illuminate Expand Partnership to Improve Cerebral Aneurysm Patient Care

Collaboration brings together Illuminate Discover360™and Viz Neuro™ Suite to advance clinical workflows

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced an expanded partnership with Softek Illuminate, Inc., an industry leader in the development of proprietary natural language processing (NLP) and AI software that discovers at-risk patients from electronic medical records (EMR), assesses disease severity, and facilitates follow-up surveillance for a variety of diseases. This partnership will enable healthcare providers to make timely decisions for patients with cerebral aneurysms while ensuring patients are not lost to follow-up.

“An estimated 6.7 million people in the United States have an unruptured brain aneurysm. Through our collaboration with Illuminate, we have the opportunity to detect and monitor aneurysm more effectively by using AI-powered tools that prevent patients from falling through the cracks,” said Jieun Choe, Chief Product & Marketing Officer at Viz.ai. “We are confident this collaboration will help more patients get the continuity of care and treatment they need to reduce aneurysm rupture.”

According to the Brain Aneurysm Foundation, approximately 30,000 people in the U.S. suffer a brain aneurysm rupture each year, leading to serious health issues and, in 50% of cases, death. Viz Aneurysm™ leverages AI to automatically analyze computed tomography angiograms (CTAs) for suspected cerebral aneurysm and streamline referrals. Illuminate’s Discovery360 incorporates the people, process, and technology to identify and monitor lost aneurysm patients. After screening nearly 1,200 CTAs for stroke evaluation across eight stroke centers, Viz Aneurysm helped determine that 85% of aneurysms had not been previously referred to neurology for follow-up.¹ Together, Viz Aneurysm and Illuminate’s Discovery360 equip care teams with the clinical insights they need to ensure timely diagnosis and patient follow-up.

“We are pleased to partner with Viz.ai to provide an end-to-end workflow, including follow-up surveillance and disease management, by combining our best-in-class technologies,” said Cole Erdmann, CEO of Illuminate. “This will ensure patients and physicians are able to make the best care decisions ultimately preventing ruptures.”

For more information on the Viz Neuro Suite, please visit https://www.viz.ai/neuro.

¹Kim, Hyun‐Woo et al. 2023. “Machine Learning–Enabled Detection of Unruptured Cerebral Aneurysms Improves Detection Rates and Clinical Care.” Stroke: Vascular and Interventional Neurology 3(6). doi:10.1161/svin.123.000938.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One^TM is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit Viz.ai.

About Illuminate, Inc.

Illuminate is the industry leading discovery, follow-up, and patient management company. Combining world class NLP and AI with integrated clinical workflows, the Illuminate Platform allows organizations to deliver the highest quality care throughout a patient’s journey. Illuminate’s mission is to ensure all patients are being managed by the right care team at the right time.